SOUTH SAN FRANCISCO, Calif., Aug. 23, 2024 /PRNewswire/ — IDEAYA Biosciences (NASDAQ:), Inc. (NASDAQ: IDYA), a precision drugs oncology firm dedicated to the invention and improvement of focused therapeutics, at present introduced that, on August 19, 2024, the Compensation Committee of IDEAYA’s Board of Administrators granted non-qualified inventory choices to buy an mixture of 150,000 shares of the Firm’s frequent inventory to a newly employed worker. The inventory choices had been granted below the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement materials to such particular person coming into into employment with IDEAYA in accordance with Nasdaq Itemizing Rule 5635(c)(4).
The 2023 Inducement Plan is used solely for the grant of fairness awards to people who weren’t beforehand staff of IDEAYA, or following a bona fide interval of non-employment, as an inducement materials to such people’ coming into into employment with IDEAYA, pursuant to Nasdaq Itemizing Rule 5635(c)(4).
The inventory choices have an train worth of $39.06 per share, which is the same as the closing worth of IDEAYA’s frequent inventory on The Nasdaq International Choose Market on the date of grant. The inventory choices have a 10-year time period and can vest over 4 years, with 25% of the choices vesting on the primary anniversary of the vesting graduation date and the remaining 75% of the choices vesting in equal month-to-month installments over the three years thereafter. Vesting of the inventory choices is topic to such worker’s continued service to IDEAYA on every vesting date.
About IDEAYA Biosciences
IDEAYA is a precision drugs oncology firm dedicated to the invention and improvement of focused therapeutics for affected person populations chosen utilizing molecular diagnostics. IDEAYA’s strategy integrates capabilities in figuring out and validating translational biomarkers with drug discovery to pick out affected person populations most definitely to profit from its focused therapies. IDEAYA is making use of its early analysis and drug discovery capabilities to artificial lethality “ which represents an rising class of precision drugs targets.
Investor and Media Contact
IDEAYA BiosciencesAndres Ruiz BrisenoSenior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
